Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISIC-1 dose-finding study of PTT-4256 in solid tumors
2025-522944-41-00Phase 2Authorised
- Sponsor
- Pathios Therapeutics
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of PTT-4256 and nivolumab in Nonhematologic neoplasms, renal cell carcinoma (RCC), clear cell renal cell carcinoma (ccRCC) and 2 more (4 arms), sponsored by Pathios Therapeutics. Primary endpoint: Safety and tolerability. Planned start Feb 2026; status: authorised.
02
Drugs
PTT-4256nivolumab
03
Conditions
Nonhematologic neoplasmsrenal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)papillary renal cell carcinoma (PRCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-522944-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522944-41-00.